City

Clinical trials near Austin, United States

Active studies with a listed research site in Austin, United States.

34active studies

18recruiting now

21countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Condition

ALN-PNP, TirzepatideTreatment

United States6 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-10 · NCT07527910See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowPhase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Obesity, OverweightCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

United States11 locations

Novo Nordisk A/SSponsor

Updated 2026-06-25 · NCT07607587See eligibility →

Recruiting nowPhase 1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Cardiometabolic DiseaseCondition

AMG 513, PlaceboTreatment

United States10 locations

AmgenSponsor

Updated 2026-06-22 · NCT06585462See eligibility →

Recruiting nowPhase 2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Obesity and Cardiovascular RiskCondition

Oral BGE-102, Oral Placebo Matching BGE-102Treatment

Puerto Rico, United States13 locations

BioAge Labs, Inc.Sponsor

Updated 2026-06-18 · NCT07656727See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Obesity & OverweightCondition

CX11, PlaceboTreatment

United States2 locations

Corxel PharmaceuticalsSponsor

Updated 2026-06-17 · NCT07652047See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowNot applicable

Mothers and CareGivers Investing in Children Study 2.0

Childhood Obesity Prevention, Parenting BehaviorCondition

MAGIC-FEED, MAGIC-SAFETreatment

United States2 locations

University of Texas at AustinSponsor

Updated 2026-06-10 · NCT06719102See eligibility →

Recruiting nowNot applicable

Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

Obesity, Women (Between 30 to 60 Years Old)Condition

Protein Rich FoodsTreatment

United States2 locations

University of Texas at AustinSponsor

Updated 2026-06-09 · NCT07480109See eligibility →

Recruiting nowPhase 2

Semaglutide for Post-Smoking Cessation Weight Management

Obesity, OverweightCondition

semaglutide 2.4mg, PlaceboTreatment

United States2 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2026-02-11 · NCT06173778See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Obesity, OverweightCondition

RO7204239, RO7204239 Matching PlaceboTreatment

Poland, Spain35 locations

Hoffmann-La RocheSponsor

Updated 2026-08-11 · NCT06965413See eligibility →

Active, not recruitingPhase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

ObesityCondition

Semaglutide, PlaceboTreatment

Austria, Belgium56 locations

Novo Nordisk A/SSponsor

Updated 2026-08-07 · NCT05726227See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

RO7795081, SemaglutideTreatment

Hungary, Poland50 locations

Hoffmann-La RocheSponsor

Updated 2026-07-07 · NCT07112872See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingNot applicable

Mothers And careGivers Investing in Children

Obesity, Childhood, ParentingCondition

Obesity Prevention Group, Obesity Prevention Group + Food BoxesTreatment

United States2 locations

University of Texas at AustinSponsor

Updated 2026-04-28 · NCT04177472See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Obese, ObesityCondition

Aleniglipron, PlaceboTreatment

United States16 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-04-27 · NCT07400588See eligibility →

Active, not recruitingNot applicable

Project Sueño: Sleep & Understanding Early Nutrition in Obesity

Infant Overweight, Infant ObesityCondition

Centering Parenting, Bright by TextTreatment

United States1 locations

University of Texas at AustinSponsor

Updated 2026-04-09 · NCT06117631See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 Body Composition Study

Obesity, Overweight, or Chronic Weight ManagementCondition

aleniglipron or placeboTreatment

United States11 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-03-03 · NCT07169942See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Austin, United States

Current studies

Related cities